Catalyst

Slingshot members are tracking this event:

Phase 1/2 data of Sarepta's (SRPT) MYO-101 in Duchenne muscular dystrophy - LGMD2E due February 27, 2019

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
SRPT Community voting in process
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Myo-101, Duchenne Muscular Dystrophy, Lgmd2e, Phase 1/2 Data